Full Press Release Details
CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss financial results for the fourth quarter ended December 31, 2025, and recent business progress.
Conference Call and Webcast Information:
Date: Thursday, March 19, 2026 at 4:30 PM ET
Participant Dial-in (US): 1-877-407-0792
Participant Dial-in (International): 1-201-689-8263
Webcast Access:Click Here
A replay of the webcast will be available in the Investors section of the Relmada website athttps://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visitwww.relmada.com